Ergomed plc Director's Dealing (4891B)
11 Febrero 2022 - 10:06AM
UK Regulatory
TIDMERGO
RNS Number : 4891B
Ergomed plc
11 February 2022
Ergomed plc
Director's Dealing
Guildford, UK - 11 February 2022 : Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, announces that
on 11 February 2022, Dr Miroslav Reljanović, Executive Chairman of
Ergomed, transferred 150,000 ordinary shares of 1p each in the
Company ("Ordinary Shares") to an employee of the Company. The
transfer took place following an exercise of options under an
option agreement dated 30 November 2016 between Dr Reljanović and
the relevant employee and the exercise price was 1p per ordinary
share.
Following the transfer, Dr Reljanović holds 9,529,297 ordinary
shares representing 19.39 % of the Company's issued share
capital.
The relevant notifications set out below are provided in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Miroslav Reljanović
--------------------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Executive Chairman
--------------------------------------- -----------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Ergomed plc
--------------------------------------- -----------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
--------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument GB00BN7ZCY67
Identification
code
--------------------------------------- -----------------------------------
b) Nature of the Transfer of shares
transaction
--------------------------------------- -----------------------------------
c) Currency GBP
--------------------------------------- -----------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------------------- ----------------- ----------------
GBP0.01 150,000
-------------------------------------------------------------- ----------------
e) Aggregated information
- Aggregated
volume 150,000
- Price GBP0.01
- Aggregated GBP1,500
total
--------------------------------------- -----------------------------------
f) Date of the 11 February 2022
transaction
--------------------------------------- -----------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------------------- -----------------------------------
ENDS
Enquiries :
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr. Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand and a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO). For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAKAFFEDAEFA
(END) Dow Jones Newswires
February 11, 2022 11:06 ET (16:06 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024